The University of Washington has joined the Alliance for Therapies in Neuroscience (ATN), a long-term research partnership between academia and industry geared to transform the fight against brain diseases and disorders of the central nervous system.
Launched in 2021 by the University of California, San Francisco, UC Berkeley, Genentech — a member of the Roche group — and Roche Holding AG, the ATN seeks to accelerate the development of new therapies for a broad range of brain and central nervous system conditions, such as Alzheimer’s disease, Lou Gehrig’s disease, Huntington’s disease, Parkinson’s disease, autism, depression and psychiatric disorders. As part of the ATN, Genentech and Roche committed up to $53 million over 10 years for research at the ATN’s participating academic institutions, a collaboration that is unique for both its duration and the breadth of its ambitions.
